GlassScriptPhysician profile
Jason Bermak
NPI 1093844128
$953,212.49
in general payments reported to CMS, 2019-2025
17 companies · $84K in 2025
The $84K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308K · 2020: $47K · 2021: $90K · 2022: $146K · 2023: $165K · 2024: $113K · 2025: $84K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $288K · Travel and Lodging: $34K · Consulting Fee: $33K · Food and Beverage: $6,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $288,188.75 |
| Travel and Lodging | $34,357.47 |
| Consulting Fee | $33,077.50 |
| Food and Beverage | $6,404.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $342,138.92 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $325,149.67 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $87,097.52 | 2019 | |
| Sunovion Pharmaceuticals INC. | $73,565.83 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $39,138.44 | 2019-2021 | |
| Alkermes, INC. | $30,222.59 | 2019-2024 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $23,326.47 | 2019 | |
| Axsome Therapeutics, INC. | $20,850.35 | 2022-2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $8,882.64 | 2024 | |
| H. Lundbeck A S | $2,449.29 | 2019 | |
| Vanda Pharmaceuticals INC. | $310.09 | 2022-2024 | Fanapt |
| Abbvie INC. | $40.68 | 2021-2022 | |
| Allergan, INC. | $40.00 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Bermak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.